PHARMACOLOGICAL BLOCKAGE OF SELECTIVE CANNABINOID-1 RECEPTOR

选择性大麻素 1 受体的药理学阻断

• 批准号: 7562466
• 负责人: ELIZABETH PARKS
• 金额: $ 2.68万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562466
• 关键词: Alcohols; Body Weight decreased; Cannabinoids; Computer Retrieval of Information on Scientific Projects Database; Condition; Development; Diabetes Mellitus; Drug usage; Fatty acid glycerol esters; Funding; Grant; Human; Individual; Infusion procedures; Institution; Lipoproteins; Liver; Measures; Obesity; Pilot Projects; Protocols documentation; Relative (related person); Research; Research Personnel; Resources; Risk Factors; Source; Triglycerides; United States National Institutes of Health; design; insulin sensitivity; nonalcoholic steatohepatitis; receptor; rimonabant; stable isotope

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A primary aim of this project is to study the effect of Rimonabant, a drug used for weight loss in humans, in reducing liver fat, a condition called NASH, nonalcoholic steatohepatitis, found in individuals who consume little or no alcohol. Obesity and diabetes are the two strongest risk factors for the development of NASH in humans. This pilot study has been designed to 1) allow changes in insulin sensitivity that can occur with weight loss, 2) demonstrate our ability to perform the stable isotope infusion protocols, and 3) measure the relative sources of fats (triglycerides) that are secreted in lipoproteins and stored in the liver in NASH with Rimonabant.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该项目的主要目的是研究Rimonabant（一种用于人类体重减轻的药物）的作用，在减少肝脏脂肪（一种称为NASH，非酒精性脂肪性肝炎的疾病）中，在少量或没有酒精的人中发现。 肥胖和糖尿病是人类纳什发展的两个最强风险因素。这项试验研究已被设计为1）允许体重减轻时可能发生的胰岛素敏感性的改变，2）证明我们执行稳定的同位素输注方案的能力； 3）测量在脂蛋白中分泌的脂肪（甘油三酸酯）的相对来源，这些脂肪（甘油三酸酯）被脂蛋白分泌并储存在Nash中，并与Rimononabant持续存在。